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Epidemiological studies have demonstrated an increased prevalence of birth defects and
intrauterine growth restriction (IUGR) among infants born prematurely suggesting they
share common biological determinants. The identification of key regulatory pathways con-
tributing to this nexus is essential to ongoing efforts to develop effective intervention
strategies. Plac1 is a paternally imprinted and X-linked gene that conforms to this paradigm.
Examination of a mutant mouse model has confirmed that Plac1 is essential for normal
placental development and function. Moreover, it is expressed throughout the developing
embryo indicating that it also has broad relevance to embryogenesis. Most notably, its
absence in the developing embryo is associated with abnormal brain development and an
increased risk of lethal, postnatal hydrocephalus identifying it as a novel, X-linked determi-
nant of brain development.The essential and non-redundant roles of Plac1 in placental and
neurological development represent a novel regulatory paradigm for embryonic growth
and pregnancy maintenance. Regulatory pathways influenced, in part, by Plac1 are likely
to contribute to the observed nexus of IUGR, prematurity, and birth defects.
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INTRODUCTION
In the United States, birth defects and prematurity are the major
causes of infant mortality and long-term disability in children (1).
Globally, intrauterine growth restriction (IUGR) also emerges as a
major determinant of infant mortality and morbidity (2). Together
they impose heavy medical, social, and economic burdens on indi-
viduals, families, communities, and national development. Often
considered as separate entities, increasing evidence suggests they
are rooted in common biological pathways. Innovative approaches
aimed at reducing their prevalence and associated morbidities will
require fundamentally new knowledge regarding the regulatory
pathways they share. We will review the evidence supporting their
common origins. We will also review a recently identified X-linked
gene, Plac1, which is essential to both placental and embryonic
development and likely contributes to regulatory pathways that
link these three outcomes.
EPIDEMIOLOGICAL EVIDENCE LINKING PREMATURITY AND
STRUCTURAL BIRTH DEFECTS
Epidemiological studies have demonstrated an unambiguous
association between being born prematurely and having a BD
(3, 4). In fact, the prevalence of BDs increases progressively
as gestational age decreases. The defects most strongly associ-
ated with prematurity involve the central nervous system (CNS)
(Prevalence Ratio= 16.23), followed by respiratory tract defects
(PR= 11.51), cardiovascular defects (PR= 9.29), gastrointesti-
nal defects (PR= 4.98), and genitourinary defects (PR= 4.09).
This epidemiological linkage is not surprising. Regulatory interac-
tions required for placental morphogenesis, a fetal tissue uniquely
required to establish and maintain pregnancy, are also required
for the development of other fetal organs. Signaling mecha-
nisms known to be relevant to both embryonic and extra-
embryonic development include HuR, Wnt, integrin, RxR, and
PPAR-dependent pathways (5–9). Additionally, disruptions in pla-
cental function, irrespective of the underlying cause, can secondar-
ily affect embryonic organ development (10, 11). Consequently,
disruptions in the placental developmental program are not only
likely to increase the probability for pregnancy failure but also
likely to influence the development of other fetal organs. While
progress has been made in preventing specific BDs and improving
pregnancy outcomes complicated by specific maternal conditions,
i.e., folate deficiency and diabetes, further progress requires identi-
fication of critical pathways that contribute to the “developmental
program” shared by both processes. This intuitively implicates
mechanisms underlying the complex spatial and temporal organi-
zation that define tissue morphogenesis in both the placenta and
embryo.
PREMATURITY AND INTRAUTERINE GROWTH RESTRICTION
Compelling evidence has emerged over the last three decades
demonstrating that infants delivered prematurely are also dispro-
portionately affected by IUGR. By inference, prematurity and birth
defects are part of a continuum that also includes IUGR. Heinonen
et al. (12), described a cohort of 120 preterm infants (≤36 weeks)
born in the Kuopio province in Finland over a 2-year period,
representing 96% of all the preterm births in that region. Birth
weight (BW), length (L), and ponderal index (PI) were recorded
and IUGR was defined as 2SD below the mean for gestational age
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for either parameter. IUGR was observed in 41% of the infants
when considering at least one growth parameter and a low PI was
the most common parameter affected (86%). Additionally, 33% of
the infants had more than one growth parameter affected. These
observations helped to change the existing pathophysiological par-
adigm by clinically linking these two entities. The high prevalence
of IUGR that was associated with their preterm infants suggested
that the sequence of events resulting in their birth actually started
weeks earlier, in utero, leading to a diminution in growth rate and
culminating in early delivery. In other words, the clinical presen-
tation of preterm labor, premature rupture of membranes, or fetal
distress represent late or end-terminal stages of a more chronic
process.
Subsequent studies in different populations supported these
findings. In 2000, Zeitlin et al. (13) reported the results of a
case–control study examining the determinants of preterm birth
using data from 16 European countries derived from the Euro-
pean Program of Occupational Risks and Pregnancy Outcome
(EUROPOP) between 1994 and 1997. A total of 4700 preterm
infants born between 22 and 36 weeks of gestation and 6460
control infants born between 37 and 40 weeks were analyzed.
Small-for-gestational age (SGA) was defined as a BW below the
10th percentile. Being SGA was found to be significantly asso-
ciated with preterm birth. Over 40% of preterm births induced
for reasons other than the premature rupture of membranes
were SGA compared with 10.7% of term infants (OR 6.41). The
association was smaller but still significant for preterm births
associated with the spontaneous or premature rupture of mem-
branes (OR 1.51). The relationship between growth restriction
and prematurity was strongest before 34 weeks gestation. Subse-
quent clinical studies were consistent with these findings. Doubilet
et al. (14) obtained estimates of fetal growth by ultrasound at
24–29.9 weeks gestation and followed the pregnancies until deliv-
ery. The measurements of infants delivered very prematurely
(24–29.9 weeks) were compared to those of infants delivering at
≥37 weeks. All growth parameters were significantly lower in the
group that delivered prematurely compared to those delivering
at term. A subsequent study recapitulated these findings. Gar-
dosi (15) obtained ultrasound-derived estimates of fetal weight
in a cohort of pregnant women later in gestation (32 weeks).
The weights of infants delivering prematurely were compared
to those that eventually delivered at term. The weights of term
infants displayed a normal distribution whereas the distribution
of weights associated with preterm infants were skewed to the left
and had a lower median, reflecting a greater proportion of IUGR
infants.
The presence of IUGR is underappreciated by most clinicians
caring for premature infants unless the infant has been severely
affected and is at the extreme end of his/her growth curve. It
is important to remain cognizant, however, of the fact that the
overall growth (BW, PI, length) trajectory of premature infants is
shifted lower, compared to infants delivering at term, even though
many have not yet reached the extreme or SGA threshold by the
time they deliver. It is clear that a significant portion of preterm
infants endure days or weeks of an adverse intrauterine environ-
ment that negatively affects their growth and increases their risk
for long-term morbidities, independent of being premature.
PREMATURITY AND THE RISK FOR COGNITIVE AND
PSYCHIATRIC IMPAIRMENT
Many studies define birth defects in terms of structurally iden-
tifiable anomalies. The March of Dimes, however, has extended
this definition to include functional neurological impairments not
apparent at birth or associated with identifiable, structural abnor-
malities (16). This more comprehensive definition of birth defects
has been validated by the cumulative weight of several important
studies demonstrating an association between prematurity and a
variety of functional neurological disorders.
PSYCHIATRIC DISORDERS
Nosarti et al. (17) performed an historical population-based
cohort study of all live-born individuals (N = 1,301,522) who were
registered in the Swedish Medical Birth Register between 1973 and
1985 and living in Sweden at age 16 by 2002. Infants born at 32–
36 weeks gestation had a 1.6-fold increase in risk of non-affective
psychosis, 1.3× the risk of depressive disorder, and 2.7× the risk
of bipolar affective disorder, compared to infants born at term.
These risks were higher for infants born earlier than 32 weeks,
2.5×, 2.9×, and 7.9× respectively.
ATTENTION-DEFICIT HYPERACTIVITY DISORDER
Similarly, Lindström et al. (18) demonstrated an association
between preterm birth and an elevated risk for ADHD in
Swedish schoolchildren. The children born between 1987 and
2000 (N = 1,180,616) who were prescribed ADHD medication
between 6 and 19 years of age were identified and linked to their
gestational age at birth. There was a significant increase in the
use of ADHD medication in children who were born prematurely.
Infants born at 23–28 weeks gestation were 2.1× more likely to
be taking these medications than children delivered at term. This
was followed by 1.6× at 29–32 weeks, 1.4× at 33–34 weeks, 1.3×
at 35–36 weeks, and 1.1× at 37–38 weeks. These findings were not
affected by genetic, perinatal, or socioeconomic status.
AUTISM SPECTRUM DISORDERS
Finally, Johnson et al. (19) conducted a prospective study of all
births <26 weeks gestation in the United Kingdom and Ireland
in 1995 and found an increased risk for autism spectrum symp-
toms and autism spectrum disorders (ASD) by middle childhood.
Subsequently, by analyzing the medical records of all children ages
0–17 years who resided in Stockholm County from 2001 to 2007
(N = 589,114), Abel et al. (20) confirmed the association between
ASD and prematurity and further demonstrated an independent
effect of fetal growth.
THE PLACENTA–BRAIN AXIS IN NEUROLOGICAL
DEVELOPMENT
Recently, Bonnin et al. (21) provided compelling evidence for
the functional interdependence of the placenta and brain dur-
ing development that may have relevance to these observations
and supports the concept of “premature placental separation” as
an independent determinant of brain development. Forebrain
circuits are important in ASD, schizophrenia, bipolar disorder,
anxiety, and depression. By creating a novel and innovative ex vivo
mouse model, Bonnin and colleagues were able to demonstrate
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that the serotonin required for forebrain development was derived
exclusively from the placenta between E10.5 and E15.5 after con-
version from tryptophan. The hindbrain was not a significant
source of forebrain serotonin until after E15.5. Thus, premature
separation from the placenta during this time would deprive the
developing brain of an essential neurotransmitter during a critical
period of development.
THE PLACENTA AS AN EXPERIMENTAL MODEL
Cumulative evidence derived from epidemiological, clinical, and
animal studies provide compelling evidence that prematurity,
structural birth defects, and cognitive/psychiatric disorders have
roots in shared biological pathways (Figure 1). Identifying and
characterizing these pathways and delineating loci that are sus-
ceptible to genetic and environmental perturbations are essential
for efforts to develop effective intervention strategies aimed at
improving outcomes. The placenta, in its unique role of provid-
ing an optimal milieu for fetal development, plays an essential
role in this regulatory context. Plac1 (Placenta-specific 1), an X-
linked, imprinted gene was recently identified that conforms to
this paradigm.
IDENTIFICATION OF THE Plac1 GENE
The Plac1 gene (placenta-specific 1) was first reported by Coc-
chia et al. (22). It maps to a region of the X chromosome
known to be important for fetal development. Large deletions
of the mouse X chromosome, spanning 200–700 kb near the
Plac1 locus, result in fetal growth retardation and neonatal death
(23). Further evidence supporting the importance of this locus
was provided by Zechner et al. (24) and Hemberger et al. (25).
The Ihpd (interspecific hybrid placental dysplasia) locus maps
in proximity to the Plac1 locus and is associated with abnor-
mal placental development where several X-linked genes may be
involved.
Northern analysis and in situ hybridization indicated Plac1
expression is restricted primarily to cells of trophoblastic lin-
eage (22, 26) hence its name Placenta-specific 1. However, recent
studies (using qRT-PCR) have demonstrated expression in mul-
tiple embryonic tissues (1–10% of placental expression). Human
PLAC1 expression is tightly linked to trophoblast differentiation
and localizes to the apical region of the cytosolic compartment
of the syncytium in proximity to the maternal-facing, microvillus
brush border membrane, consistent with function at or near the
maternal–fetal interface (27, 28).
Plac1 IN PLACENTAL DEVELOPMENT
Using a mutant mouse model, we have confirmed that Plac1 is
essential for normal placental development (29). Plac1 ablation
results in placentomegaly and IUGR. At E16.5, knockout (KO) and
heterozygous (Het) placentae deriving the Plac1-null allele from
the mother (Xm−X) weigh approximately 100% more than WT
placentae whereas the corresponding embryos weigh 7–12% less.
Histologically, the Plac1 mutants exhibit an expanded junctional
zone that migrates into the labyrinth where maternal–fetal trans-
port takes place (Figure 2A). By contrast, Het placentae that derive
the null allele from the father (XXp−) exhibit normal growth and
are histologically indistinguishable from WT placentae consistent
with paternal imprinting. While Plac1 ablation does not result in
an obligatory lethal phenotype it does reduce postnatal viability
of nullizygous offspring.
Observations from human studies have provided evidence that
PLAC1 is relevant to the establishment and maintenance of preg-
nancy by identifying it as a potential biomarker for gestational
pathologies. We reported that women can become sensitized to the
PLAC1 antigen during pregnancy and the presence of anti-PLAC1
antibodies may be associated with infertility and/or recurrent
pregnancy loss (30). This observation was confirmed by Mat-
teo et al. (31) who demonstrated increased anti-PLAC1 antibody
FIGURE 1 | Diagram illustrating the overlap of regulatory pathways involved with placental and embryonic development that, when disrupted, may
contribute to an increased risk of preterm birth or miscarriage as well as birth defects.
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FIGURE 2 | Effect of Plac1 ablation on placental and brain
development. (A) H&E stain of E16.5 mouse placentae associated with
KO and WT males. JZ, junctional zone; Lby, labyrinth. (B) Postmortem,
6-week-old Xm−X Het female with hydrocephalus. The cranium was
retracted to expose the brain tissue.
titers in women with a history of infertility. Additionally, Farina
et al. (32) and Concu et al. (33) demonstrated that PLAC1 mRNA
can be detected in maternal serum as early as 8 weeks gestation
and throughout pregnancy. Circulating PLAC1 mRNA is markedly
diminished in pregnancies associated with vaginal bleeding prior
to 20 weeks gestation. Subsequent studies demonstrated elevated
levels of circulating PLAC1 mRNA in pre-eclampsia that were
directly related to disease severity (34, 35). These findings are
consistent with a role for PLAC1 in pregnancy maintenance and
possibly as a useful biomarker of gestational pathologies.
Although there is no experimental evidence directly linking
PLAC1 to preterm delivery, it does appear to disrupt placental
development in a manner likely to interfere with its ability to adapt
to the physiological and environmental challenges of pregnancy,
thereby predisposing the pregnancy to early failure. There is some
evidence linking genes expressed at the maternal–fetal interface
with the maintenance of pregnancy. In a recent review, Anum et al.
(36) identified mutations in several genes (COL5A1, COL5A2,
COL3A1, COL1A1, COL1A2, TNXB, PLOD1, ADAMTS2, CRTAP,
LEPRE1, and ZMPSTE24) associated with connective tissue dis-
orders involving multiple organs, i.e., Ehlers–Danlos syndrome,
osteogenesis imperfecta, and restrictive dermopathy that were
also associated with prematurity, presumably resulting from the
premature rupture of membranes.
Plac1 IN BRAIN DEVELOPMENT
While characterizing the mutant mouse model we unexpectedly
discovered that Plac1 is also expressed throughout the developing
embryo where it plays a major role in brain development (37).
Plac1 ablation is associated with a 22 and 11% increased risk for
lethal hydrocephalus (HC) and other brain abnormalities in KO
males (Xm−Y) and Het females inheriting the null allele from
the mother (Xm−X), respectively (Figure 2B). By contrast, Het
females inheriting the null allele from the father (XXp−) do not
develop HC, consistent with paternal imprinting. These observa-
tions established Plac1 as a novel, X-linked determinant of brain
development.
The X chromosome is enriched for genes involved in brain
development and cognitive function and several are clustered
around Xq26.3 (38, 39), where human PLAC1 localizes. Fam-
ilies carrying microdeletions or duplications in this region
(encompassing PLAC1) report family members with a variety
of CNS defects including reduced cognitive function, micro-
cephaly, and neural tube defects (40–43). Our experimental find-
ings indicate PLAC1 is one of the genes at this locus (Xq26.3)
that is essential for normal brain development and likely con-
tributes to the clinical abnormalities observed in the reported
families.
The development of HC was the first clue that Plac1 was
involved in mouse brain development. At least 43 genetic loci
linked to hereditary HC have been identified in animal mod-
els and humans, irrespective of the presence of other associated
defects (44, 45). In fact, X-linked HC is the most common form
of hereditary HC accounting for 15–25% of primary idiopathic
HC in newborn males (46–49). A variety of CNS malformations
and clinical symptoms have been reported in humans with X-
linked HC including ataxia, reduced cognitive function, and gait
abnormalities. Linkage and pedigree analysis led to the discov-
ery of the neural cell adhesion molecule, L1CAM, as the genetic
basis for most of the cases of this disorder (50). Mouse mod-
els of L1cam mutations recapitulated the phenotypic variability
observed in humans, including the absence of overt HC in some
cases, pointing to interactions with other genetic or environmental
factors (51–53). Cases of X-linked HC, not associated with muta-
tions in L1CAM, have also been reported. A family with adult
onset X-linked HC has also been described (54), characterized by
normal pressure hydrocephalus (NPH), seizures, mental disorga-
nization, behavior problems, and urinary incontinence. Although
no gene locus has been identified, its transmission is consistent
with X chromosome linkage. Many of the genetic determinants
of developmental brain disorders have yet to be identified. These
studies underscore the importance of the X chromosome, partic-
ularly the PLAC1 locus, to brain development and neurological
function.
Plac1 PROTEIN FUNCTION
While nothing is known regarding the functional properties
of Plac1, inferences relevant to tissue morphogenesis can be
made based on its sequence. The human ORF encodes a puta-
tive protein of 212 amino acids whereas the mouse encodes a
173 amino acid product. Both contain a cleavable signal pep-
tide and are predicted to exist as extracellular peptides. Signif-
icant sequence homology (approximately 30%) exists between
Plac1 and the zona pellucida 3 (ZP3) protein, a sperm-binding
glycoprotein important for fertilization. The zona pellucida
domain (ZPD) defines a conserved family of membrane-anchored
matrix proteins having important roles in the localized organiza-
tion of epidermal cell membranes to influence organ develop-
ment and plasticity (55–61). Therefore, a key feature of Plac1’s
function is likely the modulation and integration of signal-
ing pathways linking the cell membrane to the extracellular
environment to alter cell shape, motility, and plasticity during
morphogenesis.
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SUMMARY
Recognition of the paradigm linking IUGR, prematurity, and birth
defects to common biological substrates will facilitate efforts to
understand their root causes. The identification of key regula-
tory pathways contributing to this nexus will provide important
knowledge necessary to enhance efforts to prevent, diagnose, and
intervene in troubled pregnancies and affected offspring. Plac1, an
X-linked, imprinted gene with unique relevance to placental and
embryonic development, is a novel candidate gene conforming to
this paradigm. Defining its developmental role will provide impor-
tant new insights into embryonic development and pregnancy
maintenance.
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